聖諾醫藥-B(02257.HK)公開發售超額認購5.68倍 發售價每股65.90港元
格隆匯12月29日丨聖諾醫藥-B(02257.HK)發佈公吿,公司全球發售754萬股股份,其中香港發售股份75.4萬股,國際發售股份678.6萬股,另有15%超額配股權;發售價已釐定為每股發售股份65.90港元,每手買賣單位50股;中金公司為獨家保薦人;預期股份將於2021年12月30日於聯交所主板掛牌上市。
香港發售股份已獲輕微超額認購。合共接獲6,124份有效申請,認購合共428.55萬股發售股份,相當於香港公開發售項下初步可供認購的香港發售股份總數約5.68倍。國際發售項下初步提呈發售的發售股份已獲輕微超額認購,相當於國際發售項下初步可供認購發售股份總數約1.22倍。根據與基石投資者的基石投資協議,基石投資者認購的發售股份數目現已釐定。昆明佳時清已認購279.145萬股,健新原力製藥已認購59.135萬股,合共338.28萬股發售股份。
按發售價每股65.90港元計算,假設超額配股權未獲行使,全球發售所得款項淨額估計約為3.957億港元。公司擬將所得款項淨額約57.9%用於為開發及商業化STP705提供資金;約15.6%預期將用於撥付STP707的開發;約15.4%預期將用於撥付公司的GalNAc計劃產品,如STP122G、STP133G及STP144G,以及其他臨牀前階段候選產品(倘有關研發將進一步推進公司專有的用於開發新型候選產品的GalAhead及PDoVGalNAc遞送平台);約7.3%預期將用於為其他臨牀前候選藥物的研發提供資金;及約3.8%所得款項淨額預期將用於一般企業及營運資金用途。倘超額配股權獲悉數行使,公司將就超額配股權獲行使後將予發行的113.1萬股發售股份收取額外所得款項淨額約7450萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.